Therefore, molecular docking of polydatin with BMPRR2, PHD2, HIF-2α and Arg1 was performed to investigate whether polydatin is an effective inhibitor of PAH disease progression. This evidence concerns the gene EPAS1 and pulmonary arterial hypertension.